BIIB080 Study Targets Mild Cognitive Impairment in Alzheimer's Disease
A clinical trial is underway to evaluate the safety and efficacy of BIIB080 in participants with mild cognitive impairment or mild Alzheimer's disease dementia. The study will assess whether BIIB080 can slow disease progression compared to placebo over a treatment period of up to 201 weeks.